Exploration of Targeted Anti-tumor Therapy

Home
/
Exploration of Targeted Anti-tumor Therapy
/
Articles
/
Table 1

From: Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses

Table 1. The differential effects of melatonin, TrkB and GR on immune cell pro-inflammatory activation, as well as in tumor cell survival/proliferation

Cell type		Melatonin	TrkB	GR	References
Immune cell	Macrophage	–	–	–	[84, 102, 103]
	Microglia	–	+	–	[23, 104, 105]
	NK cell	+	–	–	[106–108]
	CD8⁺ T cell	+	+	–	[56, 109, 110]
	DC	–	+	–	[111–113]
	Treg	+	?	+	[91, 114]
	Mast cell	–	?	–	[58, 80]
	Neutrophil	–	–/?	–	[52, 85, 115]
	Astrocyte	–	–/+	+	[116–118]
	MDSC	–	N/A	+	[59, 119]
Tumor cell		–	+	+	[17, 18, 93]

Return to article view

+: stimulatory; –: inhibitory; N/A: no data available; MDSC: myeloid-derived suppressor cell; ?: requires data. –/? is meant to represent some data suggestive of “inhibitory” but requires more data

Declarations

Author contributions

GA: Conceptualization, Writing—original draft, Writing—review & editing.

Conflicts of interest

The author declares there is no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Li N, Li Y, Hu J, Wu Y, Yang J, Fan H, et al. A link between mitochondrial dysfunction and the immune microenvironment of salivary glands in primary Sjogren’s syndrome. Front Immunol. 2022;13:845209. [DOI] [PubMed] [PMC]

Anderson G, Almulla AF, Reiter RJ, Maes M. Redefining autoimmune disorders’ pathoetiology: implications for mood and psychotic disorders’ association with neurodegenerative and classical autoimmune disorders. Cells. 2023;12:1237. [DOI] [PubMed] [PMC]

Anderson G. Amyotrophic lateral sclerosis pathoetiology and pathophysiology: roles of astrocytes, gut microbiome, and muscle interactions via the mitochondrial melatonergic pathway, with disruption by glyphosate-based herbicides. Int J Mol Sci. 2022;24:587. [DOI] [PubMed] [PMC]

Cassina P, Miquel E, Martínez-Palma L, Cassina A. Glial metabolic reprogramming in amyotrophic lateral sclerosis. Neuroimmunomodulation. 2021;28:204–12. [DOI] [PubMed]

Anderson G. Depression pathophysiology: astrocyte mitochondrial melatonergic pathway as crucial hub. Int J Mol Sci. 2023;24:350. [DOI] [PubMed] [PMC]

Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30. [DOI] [PubMed] [PMC]

Bai R, Cui J. Mitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria. Cancer Lett. 2023;564:216223. [DOI] [PubMed]

Anderson G. Tumor microenvironment and metabolism: role of the mitochondrial melatonergic pathway in determining intercellular interactions in a new dynamic homeostasis. Int J Mol Sci. 2023;24:311. [DOI] [PubMed] [PMC]

Kang LL, Zhang DM, Jiao RQ, Pan SM, Zhao XJ, Zheng YJ, et al. Pterostilbene attenuates fructose-induced myocardial fibrosis by inhibiting ROS-driven Pitx2c/miR-15b pathway. Oxid Med Cell Longev. 2019;2019:1243215. [DOI] [PubMed] [PMC]

10.

Samuelsson LB, Bovbjerg DH, Roecklein KA, Hall MH. Sleep and circadian disruption and incident breast cancer risk: an evidence-based and theoretical review. Neurosci Biobehav Rev. 2018;84:35–48. [DOI] [PubMed] [PMC]

11.

Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, et al. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 2016;24:324–31. [DOI] [PubMed] [PMC]

12.

De Lorenzo BHP, Novaes E Brito RR, Paslar Leal T, Piqueira Garcia N, Martins Dos Santos RM, Alvares-Saraiva AM, et al. Chronic sleep restriction impairs the antitumor immune response in mice. Neuroimmunomodulation. 2018;25:59–67. [DOI] [PubMed]

13.

Cash E, Sephton SE, Chagpar AB, Spiegel D, Rebholz WN, Zimmaro LA, et al. Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain Behav Immun. 2015;48:102–14. [DOI] [PubMed]

14.

Perrier J, Galin M, Denise P, Giffard B, Quarck G. Tackling insomnia symptoms through vestibular stimulation in patients with breast cancer: a perspective paper. Cancers (Basel). 2023;15:2904. [DOI] [PubMed] [PMC]

15.

Ancoli-Israel S, Liu L, Rissling M, Natarajan L, Neikrug AB, Palmer BW, et al. Sleep, fatigue, depression, and circadian activity rhythms in women with breast cancer before and after treatment: a 1-year longitudinal study. Support Care Cancer. 2014;22:2535–45. [DOI] [PubMed] [PMC]

16.

Megerian MF, Kim JS, Badreddine J, Hong SH, Ponsky LE, Shin JI, et al. Melatonin and prostate cancer: anti-tumor roles and therapeutic application. Aging Dis. 2023;14:840–57. [DOI] [PubMed] [PMC]

17.

Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994–1000. [DOI] [PubMed]

18.

Florido J, Martinez-Ruiz L, Rodriguez-Santana C, López-Rodríguez A, Hidalgo-Gutiérrez A, Cottet-Rousselle C, et al. Melatonin drives apoptosis in head and neck cancer by increasing mitochondrial ROS generated via reverse electron transport. J Pineal Res. 2022;73:e12824. [DOI] [PubMed] [PMC]

19.

Nguyen BT, Lin CY, Chang TK, Fong YC, Thadevoos LA, Lai CY, et al. Melatonin inhibits chondrosarcoma cell proliferation and metastasis by enhancing miR-520f-3p production and suppressing MMP7 expression. J Pineal Res. 2023;75:e12872. [DOI] [PubMed]

20.

Ma Z, Xu L, Liu D, Zhang X, Di S, Li W, et al. Utilizing melatonin to alleviate side effects of chemotherapy: a potentially good partner for treating cancer with ageing. Oxid Med Cell Longev. 2020;2020:6841581. [DOI] [PubMed] [PMC]

21.

Basirat U, Bin Tariq U, Moeen N, Jawhar ZH, Shoja SJ, Kareem AK, et al. A systematic review of the chemo/radioprotective effects of melatonin against ototoxic adverse effects induced by chemotherapy and radiotherapy. Curr Pharm Des. 2023;29:1218–29. [DOI] [PubMed]

22.

Reiter RJ, Sharma R, Rosales-Corral S, de Campos Zuccari DAP, de Almeida Chuffa LG. Melatonin: a mitochondrial resident with a diverse skill set. Life Sci. 2022;301:120612. [DOI] [PubMed]

23.

Muxel SM, Pires-Lapa MA, Monteiro AW, Cecon E, Tamura EK, Floeter-Winter LM, et al. NF-κB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N-Acetyltransferase (AA-NAT) gene. PLoS One. 2012;7:e52010. [DOI] [PubMed] [PMC]

24.

Markus RP, Fernandes PA, Kinker GS, da Silveira Cruz-Machado S, Marçola M. Immune-pineal axis – acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes. Br J Pharmacol. 2018;175:3239–50. [DOI] [PubMed] [PMC]

25.

Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. J Pineal Res. 2013;54:127–38. [DOI] [PubMed]

26.

Winge I, McKinney JA, Ying M, D’Santos CS, Kleppe R, Knappskog PM, et al. Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochem J. 2008;410:195–204. [DOI] [PubMed]

27.

Mokkawes T, de Visser SP. Melatonin activation by cytochrome P450 isozymes: how does CYP1A2 compare to CYP1A1? Int J Mol Sci. 2023;24:3651. [DOI] [PubMed] [PMC]

28.

Haduch A, Bromek E, Kuban W, Daniel WA. The engagement of cytochrome P450 enzymes in tryptophan metabolism. Metabolites. 2023;13:629. [DOI] [PubMed] [PMC]

29.

Cucielo MS, Cesário RC, Silveira HS, Gaiotte LB, Dos Santos SAA, de Campos Zuccari DAP, et al. Melatonin reverses the Warburg-type metabolism and reduces mitochondrial membrane potential of ovarian cancer cells independent of MT1 receptor activation. Molecules. 2022;27:4350. [DOI] [PubMed] [PMC]

30.

Jang SW, Liu X, Pradoldej S, Tosini G, Chang Q, Iuvone PM, et al. N-Acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci U S A. 2010;107:3876–81. [DOI] [PubMed] [PMC]

31.

Chen X, Hao B, Li D, Reiter RJ, Bai Y, Abay B, et al. Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis. J Pineal Res. 2021;71:e12755. [DOI] [PubMed]

32.

Blouin JM, Penot G, Collinet M, Nacfer M, Forest C, Laurent-Puig P, et al. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int J Cancer. 2011;128:2591–601. [DOI] [PubMed]

33.

Markus RP, Silva CL, Franco DG, Barbosa EM Jr, Ferreira ZS. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol Ther. 2010;126:251–62. [DOI] [PubMed]

34.

Steidemann MM, Liu J, Bayes K, Castro LP, Ferguson-Miller S, LaPres JJ. Evidence for crosstalk between the aryl hydrocarbon receptor and the translocator protein in mouse lung epithelial cells. Exp Cell Res. 2023;429:113617. [DOI] [PubMed]

35.

Pagliusi M Jr, Franco D, Cole S, Morais-Silva G, Chandra R, Fox ME, et al. The BDNF-TrkB pathway acts through nucleus accumbens D2 expressing neurons to mediate stress susceptible outcomes. Front Psychiatry. 2022;13:854494. [DOI] [PubMed] [PMC]

36.

Anderson G. Tumour microenvironment: roles of the aryl hydrocarbon receptor, O-GlcNAcylation, acetyl-CoA and melatonergic pathway in regulating dynamic metabolic interactions across cell types—tumour microenvironment and metabolism. Int J Mol Sci. 2021;22:141. [DOI] [PubMed] [PMC]

37.

Rezaeian AH, Dang F, Wei W. The circadian clock, aging and its implications in cancer. Neoplasia. 2023;41:100904. [DOI] [PubMed] [PMC]

38.

Terracina S, Ferraguti G, Petrella C, Bruno SM, Blaconà G, Di Certo MG, et al. Characteristic hallmarks of aging and the impact on carcinogenesis. Curr Cancer Drug Targets. 2023;23:87–102. [DOI] [PubMed]

39.

Karasek M, Reiter RJ. Melatonin and aging. Neuro Endocrinol Lett. 2002;23:14–6. [PubMed]

40.

Reiter RJ, Sharma R, Ma Q, Rosales-Corral SA, Acuna-Castroviejo D, Escames G. Inhibition of mitochondrial pyruvate dehydrogenase kinase: a proposed mechanism by which melatonin causes cancer cells to overcome cytosolic glycolysis, reduce tumor biomass and reverse insensitivity to chemotherapy. Melatonin Res. 2019;2:105–19. [DOI]

41.

Anderson G. Daytime orexin and night-time melatonin regulation of mitochondria melatonin: roles in circadian oscillations systemically and centrally in breast cancer symptomatology. Melatonin Res. 2019;2:1–8. [DOI]

42.

Anderson G. Why are aging and stress associated with dementia, cancer, and other diverse medical conditions? Role of pineal melatonin interactions with gut microbiome butyrate in HPA axis and cortisol awakening response regulation. Possible role of BAG-1. Melatonin Res. 2023;6:345–71. [DOI]

43.

Luo S, Hou Y, Zhang Y, Feng L, Hunter RG, Yuan P, et al. Bag-1 mediates glucocorticoid receptor trafficking to mitochondria after corticosterone stimulation: potential role in regulating affective resilience. J Neurochem. 2021;158:358–72. [DOI] [PubMed]

44.

Singh AK, Haldar C. Melatonin modulates glucocorticoid receptor mediated inhibition of antioxidant response and apoptosis in peripheral blood mononuclear cells. Mol Cell Endocrinol. 2016;436:59–67. [DOI] [PubMed]

45.

Giudice A, Aliberti SM, Barbieri A, Pentangelo P, Bisogno I, D’Arena G, et al. Potential mechanisms by which glucocorticoids induce breast carcinogenesis through Nrf2 inhibition. Front Biosci (Landmark Ed). 2022;27:223. [DOI] [PubMed]

46.

Obrador E, Salvador-Palmer R, López-Blanch R, Oriol-Caballo M, Moreno-Murciano P, Estrela JM. Survival mechanisms of metastatic melanoma cells: the link between glucocorticoids and the Nrf2-dependent antioxidant defense system. Cells. 2023;12:418. [DOI] [PubMed] [PMC]

47.

Mitre-Aguilar IB, Moreno-Mitre D, Melendez-Zajgla J, Maldonado V, Jacobo-Herrera NJ, Ramirez-Gonzalez V, et al. The role of glucocorticoids in breast cancer therapy. Curr Oncol. 2023;30:298–314. [DOI] [PubMed] [PMC]

48.

da Silveira Cruz-Machado S, Pinato L, Tamura EK, Carvalho-Sousa CE, Markus RP. Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF). PLoS One. 2012;7:e40142. [DOI] [PubMed] [PMC]

49.

da Silveira Cruz-Machado S, Carvalho-Sousa CE, Tamura EK, Pinato L, Cecon E, Fernandes PA, et al. TLR4 and CD14 receptors expressed in rat pineal gland trigger NFKB pathway. J Pineal Res. 2010;49:183–92. [DOI] [PubMed]

50.

Qiu J, Zhang J, Zhou Y, Li X, Li H, Liu J, et al. MicroRNA-7 inhibits melatonin synthesis by acting as a linking molecule between leptin and norepinephrine signaling pathways in pig pineal gland. J Pineal Res. 2019;66:e12552. [DOI] [PubMed]

51.

Dwyer AR, Perez Kerkvliet C, Truong TH, Hagen KM, Krutilina RI, Parke DN, et al. Glucocorticoid receptors drive breast cancer cell migration and metabolic reprogramming via PDK4. Endocrinology. 2023;164:bqad083. Erratum in: Endocrinology. 2023;164:bqad101. [DOI] [PubMed] [PMC]

52.

Jia WY, Zhang JJ. Effects of glucocorticoids on leukocytes: genomic and non-genomic mechanisms. World J Clin Cases. 2022;10:7187–94. [DOI] [PubMed] [PMC]

53.

Soichot M, Vaast A, Vignau J, Guillemin GJ, Lhermitte M, Broly F, et al. Characterization of functional polymorphisms and glucocorticoid-responsive elements in the promoter of TDO2, a candidate gene for ethanol-induced behavioural disorders. Alcohol Alcohol. 2013;48:415–25. [DOI] [PubMed]

54.

Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, et al. Tumor-repopulating cells induce pd-1 expression in CD8⁺ T cells by transferring kynurenine and AhR activation. Cancer Cell. 2018;33:480–94.e7. [DOI] [PubMed]

55.

Hu Y, Liu Z, Tang H. Tryptophan 2,3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: a meta-analysis and bioinformatics analysis. Front Oncol. 2022;12:977640. [DOI] [PubMed] [PMC]

56.

Martins Nascentes Melo L, Herrera-Rios D, Hinze D, Löffek S, Oezel I, Turiello R, et al. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma. J Immunother Cancer. 2023;11:e004150. [DOI] [PubMed] [PMC]

57.

Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci. 2010;1193:48–59. [DOI] [PubMed]

58.

Huo C, Tang Y, Li X, Han D, Gu Q, Su R, et al. Melatonin alleviates lung injury in H1N1-infected mice by mast cell inactivation and cytokine storm suppression. PLoS Pathog. 2023;19:e1011406. [DOI] [PubMed] [PMC]

59.

Mu Q, Najafi M. Modulation of the tumor microenvironment (TME) by melatonin. Eur J Pharmacol. 2021;907:174365. [DOI] [PubMed]

60.

Wang K, Cai R, Fei S, Chen X, Feng S, Zhang L, et al. Melatonin enhances anti-tumor immunity by targeting macrophages PD-L1 via exosomes derived from gastric cancer cells. Mol Cell Endocrinol. 2023;568-569:111917. [DOI] [PubMed]

61.

Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol. 2020;42:669–80. [DOI] [PubMed]

62.

Kim MJ, Choi GE, Chae CW, Lim JR, Jung YH, Yoon JH, et al. Melatonin-mediated FKBP4 downregulation protects against stress-induced neuronal mitochondria dysfunctions by blocking nuclear translocation of GR. Cell Death Dis. 2023;14:146. [DOI] [PubMed] [PMC]

63.

Khadka S, Druffner SR, Duncan BC, Busada JT. Glucocorticoid regulation of cancer development and progression. Front Endocrinol (Lausanne). 2023;14:1161768. [DOI] [PubMed] [PMC]

64.

Sathe A, Ayala C, Bai X, Grimes SM, Lee B, Kin C, et al. GITR and TIGIT immunotherapy provokes divergent multi-cellular responses in the tumor microenvironment of gastrointestinal cancers. BioRxiv [Preprint]. 2023 [cited 2023 Mar 15]. Available from: https://www.biorxiv.org/content/10.1101/2023.03.13.532299v1

65.

Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med. 2007;13:579–86. [DOI] [PubMed]

66.

Zhang J, Miki Y, Iwabuchi E, Xu J, Kanai A, Sagara Y, et al. Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients. Breast Cancer Res Treat. 2023;200:323–35. [DOI] [PubMed]

67.

Sang Y, Kong P, Zhang S, Zhang L, Cao Y, Duan X, et al. SGK1 in human cancer: emerging roles and mechanisms. Front Oncol. 2021;10:608722. [DOI] [PubMed] [PMC]

68.

Koyanagi S, Kusunose N, Taniguchi M, Akamine T, Kanado Y, Ozono Y, et al. Glucocorticoid regulation of ATP release from spinal astrocytes underlies diurnal exacerbation of neuropathic mechanical allodynia. Nat Commun. 2016;7:13102. [DOI] [PubMed] [PMC]

69.

Wu C, Chen Z, Xiao S, Thalhamer T, Madi A, Han T, et al. SGK1 governs the reciprocal development of Th17 and regulatory T cells. Cell Rep. 2018;22:653–65. [DOI] [PubMed] [PMC]

70.

Yuan SY, Liu J, Zhou J, Lu W, Zhou HY, Long LH, et al. AMPK mediates glucocorticoids stress-induced downregulation of the glucocorticoid receptor in cultured rat prefrontal cortical astrocytes. PLoS One. 2016;11:e0159513. [DOI] [PubMed] [PMC]

71.

Jiang D, Fu C, Xiao J, Zhang Z, Zou J, Ye Z, et al. SGK1 attenuates oxidative stress-induced renal tubular epithelial cell injury by regulating mitochondrial function. Oxid Med Cell Longev. 2019;2019:2013594. [DOI] [PubMed] [PMC]

72.

Ghani MJ, Gu W, Chen Z, Canessa CM. Lipid droplets and autophagosomes together with chaperones fine-tune expression of SGK1. J Cell Mol Med. 2022;26:2852–65. [DOI] [PubMed] [PMC]

73.

Sierra-Ramos C, Velazquez-Garcia S, Vastola-Mascolo A, Hernández G, Faresse N, Alvarez de la Rosa D. SGK1 activation exacerbates diet-induced obesity, metabolic syndrome and hypertension. J Endocrinol. 2020;244:149–62. [DOI] [PubMed]

74.

Tran TXM, Kim S, Park B. Changes in metabolic syndrome and the risk of breast and endometrial cancer according to menopause in Korean women. Epidemiol Health. 2023;45:e2023049. [DOI] [PubMed]

75.

Deng Y, Xiao Y, Yuan F, Liu Y, Jiang X, Deng J, et al. SGK1/FOXO3 signaling in hypothalamic POMC neurons mediates glucocorticoid-increased adiposity. Diabetes. 2018;67:569–80. [DOI] [PubMed]

76.

González-Fernández R, Ávila J, Arteaga MF, Canessa CM, Martín-Vasallo P. The neuronal-specific SGK1.1 (SGK1_v2) kinase as a transcriptional modulator of BAG4, Brox, and PPP1CB genes expression. Int J Mol Sci. 2015;16:7462–77. [DOI] [PubMed] [PMC]

77.

Anderson G, Carbone A, Mazzoccoli G. Tryptophan metabolites and aryl hydrocarbon receptor in severe acute respiratory syndrome, coronavirus-2 (SARS-CoV-2) pathophysiology. Int J Mol Sci. 2021;22:1597. [DOI] [PubMed] [PMC]

78.

Fenton CG, Crastin A, Martin CS, Suresh S, Montagna I, Hussain B, et al. 11β-Hydroxysteroid dehydrogenase type 1 within osteoclasts mediates the bone protective properties of therapeutic corticosteroids in chronic inflammation. Int J Mol Sci. 2022;23:7334. [DOI] [PubMed] [PMC]

79.

Ricci E, Roselletti E, Gentili M, Sabbatini S, Perito S, Riccardi C, et al. Glucocorticoid-induced leucine zipper-mediated TLR2 downregulation accounts for reduced neutrophil activity following acute DEX treatment. Cells. 2021;10:2228. [DOI] [PubMed] [PMC]

80.

Yamada K, Sato H, Sakamaki K, Kamada M, Okuno Y, Fukuishi N, et al. Suppression of IgE-independent degranulation of murine connective tissue-type mast cells by dexamethasone. Cells. 2019;8:112. [DOI] [PubMed] [PMC]

81.

Yi K, Jo S, Song W, Lee HI, Kim HJ, Kang JH, et al. Analysis of single-cell transcriptome and surface protein expression in ankylosing spondylitis identifies OX40-positive and glucocorticoid-induced tumor necrosis factor receptor–positive pathogenic Th17 cells. Arthritis Rheumatol. 2023;75:1176–86. [DOI] [PubMed]

82.

Lim J, Lin EV, Hong JY, Vaidyanathan B, Erickson SA, Annicelli C, et al. Induction of natural IgE by glucocorticoids. J Exp Med. 2022;219:e20220903. [DOI] [PubMed] [PMC]

83.

Oh IJ, Kim KS, Kim YC, Park JY, Yoo KY, Do SH, et al. Altered hypothalamus-pituitary-adrenal axis function: a potential underlying biological pathway for multiple concurrent symptoms in patients with advanced lung cancer. Psychosom Med. 2019;81:41–50. [DOI] [PubMed]

84.

Xu MM, Kang JY, Ji S, Wei YY, Wei SL, Ye JJ, et al. Melatonin suppresses macrophage M1 polarization and ROS-mediated pyroptosis via activating ApoE/LDLR pathway in influenza a-induced acute lung injury. Oxid Med Cell Longev. 2022;2022:2520348. [DOI] [PubMed] [PMC]

85.

Ren DL, Sun AA, Li YJ, Chen M, Ge SC, Hu B. Exogenous melatonin inhibits neutrophil migration through suppression of ERK activation. J Endocrinol. 2015;227:49–60. [DOI] [PubMed]

86.

Li M, Hao B, Zhang M, Reiter RJ, Lin S, Zheng T, et al. Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development. Signal Transduct Target Ther. 2021;6:330. [DOI] [PubMed] [PMC]

87.

Kassayová M, Bobrov N, Strojný L, Orendáš P, Demečková V, Jendželovský R, et al. Anticancer and immunomodulatory effects of lactobacillus plantarum LS/07, inulin and melatonin in NMU-induced rat model of breast cancer. Anticancer Res. 2016;36:2719–28. [PubMed]

88.

Chan YT, Tan HY, Lu Y, Zhang C, Cheng CS, Wu J, et al. Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Acta Pharm Sin B. 2023;13:1554–67. [DOI] [PubMed] [PMC]

89.

Zeng L, He J, Liu C, Zhang F, Zhang Z, Chen H, et al. Melatonin attenuates ropivacaine-induced apoptosis by inhibiting excessive mitophagy through the Parkin/PINK1 pathway in PC12 and HT22 cells. Inflammation. 2022;45:725–38. [DOI] [PubMed]

90.

Chen L, Liu L, Li Y, Gao J. Melatonin increases human cervical cancer HeLa cells apoptosis induced by cisplatin via inhibition of JNK/Parkin/mitophagy axis. In Vitro Cell Dev Biol Anim. 2018;54:1–10. [DOI] [PubMed]

91.

Huang J, Li Z, Hu Y, Li Z, Xie Y, Huang H, et al. Melatonin, an endogenous hormone, modulates Th17 cells via the reactive-oxygen species/TXNIP/HIF-1α axis to alleviate autoimmune uveitis. J Neuroinflammation. 2022;19:124. [DOI] [PubMed] [PMC]

92.

Hakami MA, Alotaibi BS, Hazazi A, Shafie A, Alsaiari AA, Ashour AA, et al. Identification of potential inhibitors of tropomyosin receptor kinase B targeting CNS-related disorders and cancers. J Biomol Struct Dyn. 2023;[Epub ahead of print]. [DOI] [PubMed]

93.

Tian J, Cheng H, Wang N, Wang C. SLERT, as a novel biomarker, orchestrates endometrial cancer metastasis via regulation of BDNF/TRKB signaling. World J Surg Oncol. 2023;21:27. [DOI] [PubMed] [PMC]

94.

Shahar O, Pereman I, Khamisie H, Ezov N, Danay O, Khattib A, et al. Compounds originating from the edible mushroom Auricularia auricula-judae inhibit tropomyosin receptor kinase B activity. Heliyon. 2023;9:e13756. [DOI] [PubMed] [PMC]

95.

Li Y, Wei C, Wang W, Li Q, Wang ZC. Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours. J Pathol Clin Res. 2023;9:89–99. [DOI] [PubMed] [PMC]

96.

Anderson G. Endometriosis pathoetiology and pathophysiology: roles of vitamin A, estrogen, immunity, adipocytes, gut microbiome and melatonergic pathway on mitochondria regulation. Biomol Concepts. 2019;10:133–49. [DOI] [PubMed]

97.

Zhou YQ, Bao TS, Xie JX, Yao LL, Yu ST, Li Q, et al. The SLITRK4-CNPY3 axis promotes liver metastasis of gastric cancer by enhancing the endocytosis and recycling of TrkB in tumour cells. Cell Oncol (Dordr). 2023;46:1049–67. [DOI] [PubMed]

98.

Moriwaki K, Wada M, Kuwabara H, Ayani Y, Terada T, Higashino M, et al. BDNF/TRKB axis provokes EMT progression to induce cell aggressiveness via crosstalk with cancer-associated fibroblasts in human parotid gland cancer. Sci Rep. 2022;12:17553. [DOI] [PubMed] [PMC]

99.

Zhang R, Zhao J, Zhao L. TRKB acts as a prognostic predictive marker in Her-2 positive breast cancer. Ann Diagn Pathol. 2022;60:152017. [DOI] [PubMed]

100.

Zhou X, Jian W, Luo Q, Zheng W, Deng X, Wang X, et al. Circular RNA_0006014 promotes breast cancer progression through sponging miR-885-3p to regulate NTRK2 and PIK3/AKT pathway. Aging (Albany NY). 2022;14:3105–28. [DOI] [PubMed] [PMC]

101.

Kang JH, Guo XD, Wang YD, Kang XW. Neuroprotective effects of N-acetylserotonin and its derivative. Neuroscience. 2023;517:18–25. [DOI] [PubMed]

102.

Bi C, Fu Y, Zhang Z, Li B. Prostaglandin E2 confers protection against diabetic coronary atherosclerosis by stimulating M2 macrophage polarization via the activation of the CREB/BDNF/TrkB signaling pathway. FASEB J. 2020;34:7360–71. [DOI] [PubMed]

103.

Caratti G, Stifel U, Caratti B, Jamil AJM, Chung KJ, Kiehntopf M, et al. Glucocorticoid activation of anti-inflammatory macrophages protects against insulin resistance. Nat Commun. 2023;14:2271. [DOI] [PubMed] [PMC]

104.

Lu X, Liu H, Cai Z, Hu Z, Ye M, Gu Y, et al. ERK1/2-dependent BDNF synthesis and signaling is required for the antidepressant effect of microglia stimulation. Brain Behav Immun. 2022;106:147–60. [DOI] [PubMed]

105.

Picard K, Bisht K, Poggini S, Garofalo S, Golia MT, Basilico B, et al. Microglial-glucocorticoid receptor depletion alters the response of hippocampal microglia and neurons in a chronic unpredictable mild stress paradigm in female mice. Brain Behav Immun. 2021;97:423–39. [DOI] [PubMed]

106.

Özçelik F, Hacımustafaoğlu F, Tanoğlu A. Modulatory effect of resveratrol and melatonin on natural killer cell activity and adrenomedullin in diabetic rats. Turk J Med Sci. 2022;52:258–67. [DOI] [PubMed]

107.

Yu X, Lu L, Liu Z, Yang T, Gong X, Ning Y, et al. Brain-derived neurotrophic factor modulates immune reaction in mice with peripheral nerve xenotransplantation. Neuropsychiatr Dis Treat. 2016;12:685–94. [DOI] [PubMed] [PMC]

108.

Bush KA, Krukowski K, Eddy JL, Janusek LW, Mathews HL. Glucocorticoid receptor mediated suppression of natural killer cell activity: identification of associated deacetylase and corepressor molecules. Cell Immunol. 2012;275:80–9. [DOI] [PubMed] [PMC]

109.

Baghban Rahimi S, Mohebbi A, Vakilzadeh G, Biglari P, Razeghi Jahromi S, Mohebi SR, et al. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells. Arch Virol. 2018;163:587–97. [DOI] [PubMed]

110.

Fauchais AL, Boumediene A, Lalloue F, Gondran G, Loustaud-Ratti V, Vidal E, et al. Brain‐derived neurotrophic factor and nerve growth factor correlate with T‐cell activation in primary Sjögren’s syndrome. Scand J Rheumatol. 2009;38:50–7. [DOI] [PubMed]

111.

Qin T, Feng D, Zhou B, Bai L, Yin Y. Melatonin suppresses LPS-induced oxidative stress in dendritic cells for inflammatory regulation via the Nrf2/HO-1 axis. Antioxidants (Basel). 2022;11:2012. [DOI] [PubMed] [PMC]

112.

Chan A, Yan J, Csurhes P, Greer J, McCombe P. Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome. J Neuroimmunol. 2015;286:42–7. [DOI] [PubMed]

113.

Yang X, Geng J, Meng H. Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis. Histol Histopathol. 2020;35:1379–89. [DOI] [PubMed]

114.

Kim D, Nguyen QT, Lee J, Lee SH, Janocha A, Kim S, et al. Anti-inflammatory roles of glucocorticoids are mediated by Foxp3⁺regulatory T Cells via a miR-342-dependent mechanism. Immunity. 2020;53:581–96.E5. [DOI] [PubMed] [PMC]

115.

Zhang SS, Liu M, Liu DN, Shang YF, Du GH, Wang YH. Network pharmacology analysis and experimental validation of kaempferol in the treatment of ischemic stroke by inhibiting apoptosis and regulating neuroinflammation involving neutrophils. Int J Mol Sci. 2022;23:12694. [DOI] [PubMed] [PMC]

116.

Cao R, Li L, Zhang W, Lu J, Wang Y, Chen Q, et al. Melatonin attenuates repeated mild traumatic brain injury-induced cognitive deficits by inhibiting astrocyte reactivation. Biochem Biophys Res Commun. 2021;580:20–7. [DOI] [PubMed]

117.

Albini M, Krawczun-Rygmaczewska A, Cesca F. Astrocytes and brain-derived neurotrophic factor (BDNF). Neurosci Res. 2023;[Epub ahead of print]. [DOI] [PubMed]

118.

Lu CL, Ren J, Mo JW, Fan J, Guo F, Chen LY, et al. Glucocorticoid receptor–dependent astrocytes mediate stress vulnerability. Biol Psychiatry. 2022;92:204–15. [DOI] [PubMed]

119.

Hou Y, Xie J, Wang S, Li D, Wang L, Wang H, et al. Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia. Cell Mol Immunol. 2022;19:764–76. [DOI] [PubMed] [PMC]

120.

Tsimpolis A, Kokkali M, Logothetis A, Kalafatakis K, Charalampopoulos I. Biphasic response of astrocytic brain-derived neurotrophic factor expression following corticosterone stimulation. Biomolecules. 2022;12:1322. [DOI] [PubMed] [PMC]

121.

Reiter RJ, Sharma R, Cucielo MS, Tan DX, Rosales-Corral S, Gancitano G, et al. Brain washing and neural health: role of age, sleep, and the cerebrospinal fluid melatonin rhythm. Cell Mol Life Sci. 2023;80:88. [DOI] [PubMed]

122.

Kannangara H, Cullen L, Miyashita S, Korkmaz F, Macdonald A, Gumerova A, et al. Emerging roles of brain tanycytes in regulating blood–hypothalamus barrier plasticity and energy homeostasis. Ann N Y Acad Sci. 2023;1525:61–9. [DOI] [PubMed] [PMC]

123.

Pan S, Yin K, Tang Z, Wang S, Chen Z, Wang Y, et al. Stimulation of hypothalamic oxytocin neurons suppresses colorectal cancer progression in mice. Elife. 2021;10:e67535. [DOI] [PubMed] [PMC]

124.

Mizuguchi T, Miyano K, Yamauchi R, Yoshida Y, Takahashi H, Yamazaki A, et al. The first structure-activity relationship study of oxytocin as a positive allosteric modulator for the µ opioid receptor. Peptides. 2023;159:170901. [DOI] [PubMed]

125.

Miyano K, Yoshida Y, Hirayama S, Takahashi H, Ono H, Meguro Y, et al. Oxytocin is a positive allosteric modulator of κ-opioid receptors but not δ-opioid receptors in the G protein signaling pathway. Cells. 2021;10:2651. [DOI] [PubMed] [PMC]

126.

Anderson G, Maes M. Role of opioidergic system in regulating depression pathophysiology. Curr Pharm Des. 2020;26:5317–34. [DOI] [PubMed]

127.

Scroope CA, Singleton Z, Hollmann MW, Parat MO. Opioid receptor-mediated and non-opioid receptor-mediated roles of opioids in tumour growth and metastasis. Front Oncol. 2021;11:792290. [DOI] [PubMed] [PMC]

128.

Sun W, Zhuang S, Cheng M, Qiu Z. Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: a pan-cancer analysis. Front Oncol. 2023;13:1134744. [DOI] [PubMed] [PMC]

129.

Yu PC, Hao CY, Fan YZ, Liu D, Qiao YF, Yao JB, et al. Altered membrane expression and function of CD11b play a role in the immunosuppressive effects of morphine on macrophages at the nanomolar level. Pharmaceuticals (Basel). 2023;16:282. [DOI] [PubMed] [PMC]

130.

Cuitavi J, Andrés-Herrera P, Meseguer D, Campos-Jurado Y, Lorente JD, Caruana H, et al. Focal mu-opioid receptor activation promotes neuroinflammation and microglial activation in the mesocorticolimbic system: alterations induced by inflammatory pain. Glia. 2023;71:1906–20. [DOI] [PubMed]

131.

Eaton-Fitch N, Du Preez S, Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Impaired TRPM3-dependent calcium influx and restoration using naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. 2022;20:94. [DOI] [PubMed] [PMC]

132.

Mazahery C, Valadkhan S, Levine AD. Transcriptomic analysis reveals receptor subclass–specific immune regulation of CD8⁺ T cells by opioids. Immunohorizons. 2020;4:420–9. [DOI] [PubMed] [PMC]

133.

Meng Y, Gao X, Chen W, Plotnikoff NP, Griffin N, Zhang G, et al. Methionine enkephalin (MENK) mounts antitumor effect via regulating dendritic cells (DCs). Int Immunopharmacol. 2017;44:61–71. [DOI] [PubMed]

134.

Juszczak M, Wolak M, Bojanowska E, Piera L, Roszczyk M. The role of melatonin membrane receptors in melatonin-dependent oxytocin secretion from the rat hypothalamo–neurohypophysial system — an in vitro and in vivo approach. Endokrynol Pol. 2016;67:507–14. [DOI] [PubMed]

135.

Anderson G. Pathoetiology and pathophysiology of borderline personality: role of prenatal factors, gut microbiome, mu- and kappa-opioid receptors in amygdala-PFC interactions. Prog Neuropsychopharmacol Biol Psychiatry. 2020;98:109782. [DOI] [PubMed]

136.

Shavali S, Ho B, Govitrapong P, Sawlom S, Ajjimaporn A, Klongpanichapak S, et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of β-endorphin an endogenous opioid. Brain Res Bull. 2005;64:471–9. [DOI] [PubMed]

137.

Wamsteeker Cusulin JI, Füzesi T, Inoue W, Bains JS. Glucocorticoid feedback uncovers retrograde opioid signaling at hypothalamic synapses. Nat Neurosci. 2013;16:596–604. [DOI] [PubMed] [PMC]

138.

Mikuma N, Kumamoto Y, Maruta H, Nitta T. Role of the hypothalamic opioidergic system in the control of gonadotropin secretion in elderly men¹. Andrologia. 1994;26:39–45. [DOI] [PubMed]

139.

Garrido MP, Hernandez A, Vega M, Araya E, Romero C. Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers. Front Endocrinol (Lausanne). 2023;14:1143261. [DOI] [PubMed] [PMC]

140.

Lalami I, Labrosse J, Cedrin-Durnerin I, Comtet M, Vinolas C, Krief F, et al. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? Reprod Biol Endocrinol. 2022;20:87. [DOI] [PubMed] [PMC]

141.

Zhang X, Zhang G, Wang J, Wang Y. Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: a systematic review. Front Endocrinol (Lausanne). 2023;14:1131715. [DOI] [PubMed] [PMC]

142.

Iqbal K, Khanum Z, Parveen A. Association of polycystic ovarian syndrome with endometrial carcinoma among premenopausal females. J Coll Physicians Surg Pak. 2023;33:531–4. [DOI] [PubMed]

143.

Kim J, Mersereau JE, Khankari N, Bradshaw PT, McCullough LE, Cleveland R, et al. Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study. Cancer Causes Control. 2016;27:403–14. [DOI] [PubMed] [PMC]

144.

Harris HR, Peres LC, Johnson CE, Guertin KA, Beeghly A, Bandera EV, et al. Racial differences in the association of endometriosis and uterine leiomyomas with the risk of ovarian cancer. Obstet Gynecol. 2023;141:1124–38. [DOI] [PubMed] [PMC]

145.

Ye J, Peng H, Huang X, Qi X. The association between endometriosis and risk of endometrial cancer and breast cancer: a meta-analysis. BMC Womens Health. 2022;22:455. [DOI] [PubMed] [PMC]

146.

Yin B, Ma ZY, Zhou ZW, Gao WC, Du ZG, Zhao ZH, et al. The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene. 2015;34:761–70. [DOI] [PubMed]

147.

Anderson G. Type I diabetes pathoetiology and pathophysiology: roles of the gut microbiome, pancreatic cellular interactions, and the ‘bystander’ activation of memory CD8⁺ T cells. Int J Mol Sci. 2023;24:3300. [DOI] [PubMed] [PMC]

148.

Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1^−/− mice. Nature. 2019;571:565–9. [DOI] [PubMed]

149.

do Carmo Buonfiglio D, Peliciari-Garcia RA, do Amaral FG, Peres R, Nogueira TC, Afeche SC, et al. Early-stage retinal melatonin synthesis impairment in streptozotocin-induced diabetic Wistar rats. Invest Ophthalmol Vis Sci. 2011;52:7416–22. [DOI] [PubMed]

150.

Dahmus JD, Kotler DL, Kastenberg DM, Kistler CA. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. J Gastrointest Oncol. 2018;9:769–77. [DOI] [PubMed] [PMC]

151.

Kouidhi S, Zidi O, Belkhiria Z, Rais H, Ayadi A, Ben Ayed F, et al. Gut microbiota, an emergent target to shape the efficiency of cancer therapy. Explor Target Antitumor Ther. 2023;4:240–65. [DOI] [PubMed] [PMC]

152.

Jin CJ, Engstler AJ, Sellmann C, Ziegenhardt D, Landmann M, Kanuri G, et al. Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation. Br J Nutr. 2016;116:1682–93. [DOI] [PubMed]

153.

Anderson G, Maes M. Gut dysbiosis dysregulates central and systemic homeostasis via suboptimal mitochondrial function: assessment, treatment and classification implications. Curr Top Med Chem. 2020;20:524–39. [DOI] [PubMed]

154.

Zhang K, Dong Y, Li M, Zhang W, Ding Y, Wang X, et al. Clostridium butyricum inhibits epithelial–mesenchymal transition of intestinal carcinogenesis through downregulating METTL3. Cancer Sci. 2023;114:3114–27. [DOI] [PubMed] [PMC]

155.

Qu R, Zhang Y, Ma Y, Zhou X, Sun L, Jiang C, et al. Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer. Adv Sci (Weinh). 2023;10:2205563. [DOI] [PubMed] [PMC]

156.

Jaye K, Chang D, Li CG, Bhuyan DJ. Gut metabolites and breast cancer: the continuum of dysbiosis, breast cancer risk, and potential breast cancer therapy. Int J Mol Sci. 2022;23:9490. [DOI] [PubMed] [PMC]

157.

Dono A, Nickles J, Rodriguez-Armendariz AG, McFarland BC, Ajami NJ, Ballester LY, et al. Glioma and the gut–brain axis: opportunities and future perspectives. Neurooncol Adv. 2022;4:vdac054. [DOI] [PubMed] [PMC]

158.

Anderson G, Reiter RJ. Glioblastoma: role of mitochondria N-acetylserotonin/melatonin ratio in mediating effects of miR-451 and aryl hydrocarbon receptor and in coordinating wider biochemical changes. Int J Tryptophan Res. 2019;12:1178646919855942. [DOI] [PubMed] [PMC]

159.

Wang Z, Qin X, Hu D, Huang J, Guo E, Xiao R, et al. Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer. Cell Rep. 2022;41:111890. [DOI] [PubMed]

160.

Ali SR, Humphreys KJ, Simpson KJ, McKinnon RA, Meech R, Michael MZ. Functional high-throughput screen identifies microRNAs that promote butyrate-induced death in colorectal cancer cells. Mol Ther Nucleic Acids. 2022;30:30–47. [DOI] [PubMed] [PMC]

161.

Sharma M, Tollefsbol TO. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition. Exp Cell Res. 2022;416:113160. [DOI] [PubMed]

162.

Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008;272:110–21. Erratum in: Cancer Lett. 2009;274:167. [DOI] [PubMed]

163.

Zaiatz-Bittencourt V, Jones F, Tosetto M, Scaife C, Cagney G, Jones E, et al. Butyrate limits human natural killer cell effector function. Sci Rep. 2023;13:2715. [DOI] [PubMed] [PMC]

164.

Tian P, Yang W, Guo X, Wang T, Tan S, Sun R, et al. Early life gut microbiota sustains liver-resident natural killer cells maturation via the butyrate-IL-18 axis. Nat Commun. 2023;14:1710. [DOI] [PubMed] [PMC]

165.

Luu M, Weigand K, Wedi F, Breidenbend C, Leister H, Pautz S, et al. Regulation of the effector function of CD8⁺ T cells by gut microbiota-derived metabolite butyrate. Sci Rep. 2018;8:14430. [DOI] [PubMed] [PMC]

166.

Jia Z, Jin J, Wang W, Wang X. The mechanism of sodium butyrate on the growth of mouse B16 melanoma cells by inhibiting the differentiation of M2-type macrophages and down-regulating the expressions of VEGF and TGF-β. Biotechnol Genet Eng Rev. 2023;[Epub ahead of print]. [DOI] [PubMed]

167.

Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun. 2020;11:2168. [DOI] [PubMed] [PMC]

168.

Wang HF, Ning F, Liu ZC, Wu L, Li ZQ, Qi YF, et al. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. Cancer Immunol Immunother. 2017;66:355–66. [DOI] [PubMed]

169.

Miletta MC, Petkovic V, Eblé A, Ammann RA, Flück CE, Mullis PE. Butyrate increases intracellular calcium levels and enhances growth hormone release from rat anterior pituitary cells via the G-protein-coupled receptors GPR41 and 43. PLoS One. 2014;9:e107388. [DOI] [PubMed] [PMC]

170.

Wang X, Duan C, Li Y, Lu H, Guo K, Ge X, et al. Sodium butyrate reduces overnutrition-induced microglial activation and hypothalamic inflammation. Int Immunopharmacol. 2022;111:109083. [DOI] [PubMed]

171.

Balasubramanian N, Sagarkar S, Jadhav M, Shahi N, Sirmaur R, Sakharkar AJ. Role for histone deacetylation in traumatic brain injury-induced deficits in neuropeptide Y in arcuate nucleus: possible implications in feeding behavior. Neuroendocrinology. 2021;111:1187–200. [DOI] [PubMed]

172.

Yu Z, Tian X, Peng Y, Sun Z, Wang C, Tang N, et al. Mitochondrial cytochrome P450 (CYP) 1B1 is responsible for melatonin-induced apoptosis in neural cancer cells. J Pineal Res. 2018;65:e12478. [DOI] [PubMed]

173.

Iesanu MI, Zahiu CDM, Dogaru IA, Chitimus DM, Pircalabioru GG, Voiculescu SE, et al. Melatonin–microbiome two-sided interaction in dysbiosis-associated conditions. Antioxidants (Basel). 2022;11:2244. [DOI] [PubMed] [PMC]

174.

Strasser B, Ticinesi A. Intestinal microbiome in normal ageing, frailty and cognition decline. Curr Opin Clin Nutr Metab Care. 2023;26:8–16. [DOI] [PubMed]

175.

Wollmuth EM, Angert ER. Microbial circadian clocks: host-microbe interplay in diel cycles. BMC Microbiol. 2023;23:124. [DOI] [PubMed] [PMC]

176.

Shukla PK, Meena AS, Pierre JF, Rao R. Central role of intestinal epithelial glucocorticoid receptor in alcohol- and corticosterone-induced gut permeability and systemic response. FASEB J. 2022;36:e22061. [DOI] [PubMed] [PMC]

177.

Vanuytsel T, van Wanrooy S, Vanheel H, Vanormelingen C, Verschueren S, Houben E, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63:1293–9. [DOI] [PubMed]

178.

Sommansson A, Nylander O, Sjöblom M. Melatonin decreases duodenal epithelial paracellular permeability via a nicotinic receptor–dependent pathway in rats in vivo. J Pineal Res. 2013;54:282–91. [DOI] [PubMed]

179.

Costantini TW, Krzyzaniak M, Cheadle GA, Putnam JG, Hageny AM, Lopez N, et al. Targeting α-7 nicotinic acetylcholine receptor in the enteric nervous system: a cholinergic agonist prevents gut barrier failure after severe burn injury. Am J Pathol. 2012;181:478–86. [DOI] [PubMed]

180.

Morris DJ, Brem AS, Odermatt A. Modulation of 11β-hydroxysteroid dehydrogenase functions by the cloud of endogenous metabolites in a local microenvironment: the glycyrrhetinic acid-like factor (GALF) hypothesis. J Steroid Biochem Mol Biol. 2021;214:105988. [DOI] [PubMed]

181.

Wu WL, Adame MD, Liou CW, Barlow JT, Lai TT, Sharon G, et al. Microbiota regulate social behaviour via stress response neurons in the brain. Nature. 2021;595:409–14. [DOI] [PubMed] [PMC]

182.

Koyama Y, Adachi M, Sekiya M, Takekawa M, Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood. 2000;96:1490–5. [PubMed]

183.

Ogawa K, Yasumura S, Atarashi Y, Minemura M, Miyazaki T, Iwamoto M, et al. Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol. 2004;40:278–84. [DOI] [PubMed]

184.

Wiechmann AF, Burden MA. Regulation of AA-NAT and HIOMT gene expression by butyrate and cyclic AMP in Y79 human retinoblastoma cells. J Pineal Res. 1999;27:116–21. [DOI] [PubMed]

185.

Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, et al. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020;6:19. [DOI] [PubMed] [PMC]

186.

Branchey L, Weinberg U, Branchey M, Linkowski P, Mendlewicz J. Simultaneous study of 24-hour patterns of melatonin and cortisol secretion in depressed patients. Neuropsychobiology. 1982;8:225–32. [DOI] [PubMed]

187.

Clemo NK, Arhel NJ, Barnes JD, Baker J, Moorghen M, Packham GK, et al. The role of the retinoblastoma protein (Rb) in the nuclear localization of BAG-1: implications for colorectal tumour cell survival. Biochem Soc Trans. 2005;33:676–8. [DOI] [PubMed]

188.

Singh P, Chan SW, Hong W. Retinoblastoma protein is functionally distinct from its homologues in affecting glucocorticoid receptor-mediated transcription and apoptosis*. J Biol Chem. 2001;276:13762–70. [DOI] [PubMed]

189.

Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All). Biochem Pharmacol. 2018;153:230–41. [DOI] [PubMed]

190.

Datta N, Chakraborty S, Basu M, Ghosh MK. Tumor suppressors having oncogenic functions: the double agents. Cells. 2021;10:46. [DOI] [PubMed] [PMC]

191.

Huo X, Wang C, Yu Z, Peng Y, Wang S, Feng S, et al. Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: An implication of the therapeutic potential. J Pineal Res. 2017;62:e12390. Erratum in: J Pineal Res. 2023;[Epub ahead of print]. [DOI] [PubMed]

192.

Alghamdi OA, King N, Andronicos NM, Jones GL, Chami B, Witting PK, et al. Molecular changes to the rat renal cotransporters PEPT1 and PEPT2 due to ageing. Mol Cell Biochem. 2019;452:71–82. [DOI] [PubMed]

193.

Im CN, Yun HH, Song B, Youn DY, Cui MN, Kim HS, et al. BIS-mediated STAT3 stabilization regulates glioblastoma stem cell-like phenotypes. Oncotarget. 2016;7:35056–70. [DOI] [PubMed] [PMC]

194.

Im CN. Combination treatment with PPARγ ligand and its specific inhibitor GW9662 downregulates BIS and 14-3-3 gamma, inhibiting stem-like properties in glioblastoma cells. Biomed Res Int. 2017;2017:5832824. [DOI] [PubMed] [PMC]

195.

Lee JJ, Lee JS, Cui MN, Yun HH, Kim HY, Lee SH, et al. BIS targeting induces cellular senescence through the regulation of 14-3-3 zeta/STAT3/SKP2/p27 in glioblastoma cells. Cell Death Dis. 2014;5:e1537. [DOI] [PubMed] [PMC]

196.

Sukhareva KS, Smolina NA, Churkina AI, Kalugina KK, Zhuk SV, Khudiakov AA, et al. Desmin mutations impact the autophagy flux in C2C12 cell in mutation-specific manner. Cell Tissue Res. 2023;393:357–75. [DOI] [PubMed] [PMC]

197.

Wolf DM, Segawa M, Kondadi AK, Anand R, Bailey ST, Reichert AS, et al. Individual cristae within the same mitochondrion display different membrane potentials and are functionally independent. EMBO J. 2019;38:e101056. [DOI] [PubMed] [PMC]

198.

Jin Z, Ji Y, Su W, Zhou L, Wu X, Gao L, et al. The role of circadian clock-controlled mitochondrial dynamics in diabetic cardiomyopathy. Front Immunol. 2023;14:1142512. [DOI] [PubMed] [PMC]

199.

Ježek P, Jabůrek M, Holendová B, Engstová H, Dlasková A. Mitochondrial cristae morphology reflecting metabolism, superoxide formation, redox homeostasis, and pathology. Antioxid Redox Signal. 2023;[Epub ahead of print]. [DOI] [PubMed]

200.

Tomar D, Thomas M, Garbincius JF, Kolmetzky DW, Salik O, Jadiya P, et al. MICU1 regulates mitochondrial cristae structure and function independently of the mitochondrial Ca²⁺ uniporter channel. Sci Signal. 2023;16:eabi8948. [DOI] [PubMed] [PMC]

201.

Yang Y, Du J, Xu R, Shen Y, Yang D, Li D, et al. Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway. Aging (Albany NY). 2020;13:493–515. [DOI] [PubMed] [PMC]

202.

Seegren PV, Harper LR, Downs TK, Zhao XY, Viswanathan SB, Stremska ME, et al. Reduced mitochondrial calcium uptake in macrophages is a major driver of inflammaging. Nat Aging. 2023;3:796–812. [DOI] [PubMed] [PMC]